Clinical Trial Detail

NCT ID NCT02213042
Title Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor positive breast cancer

Therapies

Lapatinib + Trastuzumab

Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST